Search

Search Results

Results 5291 - 5300 of 5437 for Cancer Research

Phase I clinical trial of XRX-001 for yellow fever initiated

News - 12 Jan 2010

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
Highly promising Alzheimer's and Parkinson's research

News - 17 Dec 2007

The TI Pharma project is a large-scale study into the brain material of Alzheimer's and Parkinson's patients, who gave permission to the Netherlands Brain Bank for their tissue to be used for...
India is poised to revolutionize biotechnology

News - 10 Apr 2007

India's health biotech firms are emerging as a major global player, with growing means and know-how to produce innovative as well as generic drugs and vaccines at costs small relative to those of...
Severe Acute Respiratory Syndrome (SARS) overview

News - 24 Apr 2004

Severe Acute Respiratory Syndrome (SARS) is an atypical form of pneumonia that first appeared in November 2002 in Guangdong Province, China.
Prevenar 20

Drug - 4 Sep 2026

Consumer Medicine Information (CMI) about Prevenar 20 intended for persons living in Australia.
Verorab

Drug - 15 Jul 2026

Consumer Medicine Information (CMI) about Verorab intended for persons living in Australia.
Quadracel

Drug - 15 Jul 2026

Consumer Medicine Information (CMI) about Quadracel intended for persons living in Australia.
Avaxim

Drug - 13 Jul 2026

Consumer Medicine Information (CMI) about Avaxim intended for persons living in Australia.
IPOL

Drug - 2 Jul 2026

Consumer Medicine Information (CMI) about IPOL intended for persons living in Australia.
Duoplidogrel

Drug - 3 Jun 2026

Consumer Medicine Information (CMI) about Duoplidogrel intended for persons living in Australia.

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.